Yifan Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Yifan Pharmaceutical's earnings have been declining at an average annual rate of -55%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 6.2% per year.
Key information
-55.0%
Earnings growth rate
-54.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -6.2% |
| Return on equity | -9.0% |
| Net Margin | -8.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Yifan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4,756 | -407 | 1,709 | 317 |
| 31 Mar 24 | 4,456 | -470 | 1,648 | 325 |
| 31 Dec 23 | 4,068 | -551 | 1,563 | 312 |
| 30 Sep 23 | 4,038 | 135 | 1,480 | 235 |
| 30 Jun 23 | 4,011 | 139 | 1,516 | 212 |
| 31 Mar 23 | 3,869 | 135 | 1,476 | 199 |
| 01 Jan 23 | 3,837 | 191 | 1,465 | 190 |
| 30 Sep 22 | 3,740 | 191 | 1,482 | 194 |
| 30 Jun 22 | 3,801 | 226 | 1,378 | 190 |
| 31 Mar 22 | 4,115 | 267 | 1,345 | 194 |
| 01 Jan 22 | 4,409 | 278 | 1,318 | 197 |
| 30 Sep 21 | 4,656 | 348 | 1,269 | 309 |
| 30 Jun 21 | 4,967 | 463 | 1,207 | 318 |
| 31 Mar 21 | 5,276 | 777 | 1,143 | 307 |
| 31 Dec 20 | 5,400 | 968 | 1,120 | 325 |
| 30 Sep 20 | 5,533 | 1,073 | 1,097 | 233 |
| 30 Jun 20 | 5,480 | 1,136 | 1,112 | 248 |
| 31 Mar 20 | 5,376 | 1,080 | 1,111 | 244 |
| 31 Dec 19 | 5,187 | 903 | 1,071 | 208 |
| 30 Sep 19 | 4,994 | 769 | 1,035 | 191 |
| 30 Jun 19 | 4,824 | 683 | 977 | 162 |
| 31 Mar 19 | 4,515 | 559 | 894 | 156 |
| 31 Dec 18 | 4,632 | 737 | 870 | 166 |
| 30 Sep 18 | 4,742 | 1,140 | 837 | 148 |
| 30 Jun 18 | 4,842 | 1,364 | 720 | 204 |
| 31 Mar 18 | 4,760 | 1,431 | 714 | 172 |
| 31 Dec 17 | 4,373 | 1,305 | 708 | 139 |
| 30 Sep 17 | 3,900 | 1,045 | 725 | 91 |
| 30 Jun 17 | 3,630 | 821 | 799 | 0 |
| 31 Mar 17 | 3,548 | 768 | 808 | 0 |
| 31 Dec 16 | 3,505 | 705 | 777 | 0 |
| 30 Sep 16 | 3,282 | 604 | 670 | 0 |
| 30 Jun 16 | 2,948 | 554 | 656 | 0 |
| 31 Mar 16 | 2,664 | 413 | 619 | 0 |
| 31 Dec 15 | 2,435 | 361 | 565 | 0 |
| 30 Sep 15 | 2,446 | 420 | 516 | 0 |
| 30 Jun 15 | 2,237 | 327 | 456 | 0 |
| 31 Mar 15 | 1,930 | 280 | 405 | 0 |
| 31 Dec 14 | 1,685 | 238 | 351 | 0 |
| 30 Sep 14 | 1,414 | 148 | 318 | 0 |
| 30 Jun 14 | 1,327 | 146 | 265 | 0 |
| 31 Mar 14 | 1,331 | 155 | 236 | 0 |
| 31 Dec 13 | 1,158 | 118 | 197 | 0 |
| 30 Sep 13 | 968 | 70 | 149 | 0 |
Quality Earnings: 002019 is currently unprofitable.
Growing Profit Margin: 002019 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002019 is unprofitable, and losses have increased over the past 5 years at a rate of 55% per year.
Accelerating Growth: Unable to compare 002019's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002019 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Return on Equity
High ROE: 002019 has a negative Return on Equity (-8.98%), as it is currently unprofitable.